Quest for the right Drug
CAPD - 2 תמיסה לדיאליזה צפקית CAPD 2 PERITONEAL DIALYSIS SOLUTION (CALCIUM CHLORIDE, GLUCOSE AS MONOHYDRATE, LACTIC ACID AS SODIUM, MAGNESIUM CHLORIDE, SODIUM CHLORIDE)
תרופה במרשם
תרופה בסל
נרקוטיקה
ציטוטוקסיקה
צורת מתן:
תוך-בטני : INTRA-PERITONEAL
צורת מינון:
תמיסה לדיאליזה פריטוניאלית : SOLUTION FOR PERITONEAL DIALYSIS
עלון לרופא
מינוניםPosology התוויות
Indications תופעות לוואי
Adverse reactions התוויות נגד
Contraindications אינטראקציות
Interactions מינון יתר
Overdose הריון/הנקה
Pregnancy & Lactation אוכלוסיות מיוחדות
Special populations תכונות פרמקולוגיות
Pharmacological properties מידע רוקחי
Pharmaceutical particulars אזהרת שימוש
Special Warning עלון לרופא
Physicians Leaflet
Adverse reactions : תופעות לוואי
4.8 Undesirable effects Possible adverse reactions may result from the peritoneal dialysis treatment itself or may be induced by the dialysis solution. The adverse drug reactions are ranked under the headings of reporting frequency, using the following convention: very common 1/10 common 1/100 to <1/10 uncommon 1/1,000 to <1/100 rare 1/10,000 to <1/1,000 very rare <1/10,000 not known cannot be estimated from the available data Potential adverse reactions of the peritoneal dialysis solution Metabolism and nutrition disorders - Increased blood sugar levels (common) - Increase in body weight due to the continuous uptake of glucose from the peritoneal dialysis solution (common) - Hyperlipidaemia or deterioration of pre-existing hyperlipidaemia (common) Cardiac and vascular disorders - Hypotension (uncommon) - Tachycardia (uncommon) - Hypertension (uncommon) Respiratory, thoracic and mediastinal disorders - Dyspnoea (uncommon) Renal and urinary disorders - Electrolyte disturbances, e.g. hypokalaemia (very common) - Hypercalcaemia can occur (common) if calcium intake is increased, e.g. through concomitant use of calcium-containing phosphate binders. General disorders and administration site conditions - Dizziness (uncommon) - Oedema (uncommon) - Disturbances in fluid balance (uncommon) indicated either by a rapid decrease (dehydration) or increase (hyperhydration) in body weight. Severe dehydration might occur when using solutions with higher glucose concentrations. Potential adverse reactions of the treatment mode Infections and infestations - Peritonitis (very common) indicated by a cloudy effluent. Subsequent abdominal pain, fever, and general malaise or, in very rare cases, sepsis may develop. The patient should seek medical advice immediately. The bag with the cloudy effluent should be closed with a sterile cap and assessed for microbiological contamination and for the white blood cell count. - Skin infections at the exit site and tunnel infections (very common) indicated by redness, oedema, exudations, crusts and pain at the catheter exit site. In case of skin infections at the exit site and of tunnel infections, the attending physician should be consulted as soon as possible. Respiratory, thoracic and mediastinal disorders - Dyspnoea caused by the elevated diaphragm (not known) Gastrointestinal disorders - Hernia (very common) - Abdominal distension and sensation of fullness (common) - Diarrhoea (uncommon) - Constipation (uncommon) - Encapsulating peritoneal sclerosis (not known) Injury, poisoning and procedural complications - Dialysis solution inflow and outflow disturbances (common) - Shoulder pain (common) Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Any suspected adverse events should be reported to the Ministry of Health according to the National Regulation by using an online form: https://sideeffects.health.gov.il
שימוש לפי פנקס קופ''ח כללית 1994
לא צוין
תאריך הכללה מקורי בסל
לא צוין
הגבלות
לא צוין
מידע נוסף